logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Phase 3 Study Of Torisel In Combination With Bevacizumab Fails

Pfizer Inc (PFE) Friday announced that its Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL compared with bevacizumab plus interferon-alfa-2a, or IFN-a-2a, did not meet its primary endpoint of superiority in extending progression free survival , or PFS, in the study population.

The company stated that the Phase 3 trial was carried out in the first-line treatment of patients with advanced renal cell carcinoma, or RCC, across risk groups.

The company further stated that the combination of bevacizumab and IFN-a-2a is approved as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche.

"This trial advances our knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "Additional analyses will be performed to help us understand this result. The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dealing a potentially fatal blow to a last-ditch effort by Republicans to repeal and replace Obamacare, Senator John McCain, R-Ariz., on Friday announced his opposition to a healthcare bill drafted by Senators Lindsey Graham, R-S.C., and Bill Cassidy, R-La. Reiterating his claim that Russian meddling in last year's election is a hoax, President Donald Trump has argued that the biggest influence on the election came from the media. Trump seemed to suggest in a post on Twitter on Friday that his victory in the presidential election came despite the media's... U.S. airlines collected a record $7.1 billion in revenue from fees for checked baggage and for changing or canceling reservations, reflecting a marked increase from 2010, according to a government report. The U.S. Government Accountability Office or GOA said in a report that U.S. airlines' revenue from these two fees increased to $7.1 billion in 2016 from $6.3 billion in 2010, in constant dollars.
comments powered by Disqus
Follow RTT